Is Nicergoline Effective for Memory and Cognitive Decline?

Nicergoline is a prescription drug that has been studied for dementia, vascular cognitive impairment and other disorders affecting memory, attention and behaviour. Several placebo-controlled trials reported improvements in cognitive scores or overall clinical ratings, with some benefits becoming more apparent after several months of treatment.

Most of that evidence comes from an earlier generation of dementia research. The trials used diagnostic categories and assessment methods that do not always correspond with current practice, while newer animal research has focused more on possible mechanisms than on confirming effectiveness in people.

What Is Nicergoline?

Nicergoline is a semisynthetic ergot derivative developed in the late 1960s. It was initially used as a vasoactive drug for cerebrovascular disorders and was later studied in Alzheimer’s disease, vascular dementia, post-stroke impairment, balance disorders and other conditions associated with ageing.

Most dementia trials reviewed by Winblad and colleagues used a total oral dose of 60 mg per day, generally divided into two 30 mg doses. After oral administration, nicergoline is rapidly absorbed but undergoes extensive first-pass metabolism. Its major metabolites include 1-methyl-10-alpha-methoxy-9,10-dihydrolysergol and 10-alpha-methoxy-9,10-dihydrolysergol, with CYP2D6 contributing to the latter metabolic step.

Nicergoline is sometimes described as a nootropic because it has been investigated for memory and cognitive function. The clinical evidence in these reviews concerns people with dementia, cerebrovascular disease or other diagnosed impairments. It does not establish cognitive enhancement in healthy adults.

How Could Nicergoline Affect Memory?

Nicergoline was originally regarded mainly as a cerebral vasodilator, but later research suggested a broader pharmacological profile.

As an alpha-1 adrenergic receptor antagonist, it can reduce vascular resistance and influence blood flow. Experimental research has also linked nicergoline with increased acetylcholine release, enhanced dopamine and noradrenaline turnover, altered phosphoinositide and protein kinase C signalling, and greater utilisation of glucose and oxygen in the brain. Antioxidant, neurotrophic and antiplatelet effects have also been reported.

Several of these actions could be relevant to cognitive impairment. Acetylcholine supports memory and attention, while vascular dysfunction may impair the delivery of oxygen and nutrients to brain tissue. Neurotrophic and antioxidant effects could also help protect vulnerable neurons.

The available research does not identify a single dominant mechanism. Nicergoline may act through several pathways that influence blood flow, neurotransmission, metabolism and neuronal survival.

What Did the Human Trials Find?

The main human evidence comes from older placebo-controlled studies in people with mild-to-moderate dementia. Study populations included Alzheimer’s disease, vascular dementia, multi-infarct dementia and mixed forms of cognitive impairment.

A Cochrane analysis summarised in the 2008 review found that nicergoline generally performed better than control treatment on measures of cognition, behaviour and overall clinical improvement. Pooled results favoured nicergoline on the Mini-Mental State Examination, the Sandoz Clinical Assessment-Geriatric scale and Clinical Global Impression ratings.

For the Mini-Mental State Examination, pooled results at six and twelve months favoured nicergoline. Sandoz Clinical Assessment-Geriatric scores also improved relative to control treatment, particularly after six months. Across six studies, patients receiving nicergoline were more likely to be rated as improved on global clinical assessments.

Taken together, the trials point to a modest symptomatic effect in some patients, with benefits becoming more apparent after several months of treatment.

Nicergoline in Alzheimer’s Disease

Two randomised trials specifically examined people with probable mild-to-moderate Alzheimer’s disease.

A European multicentre trial included 346 patients treated with nicergoline or placebo for six months. The mean cognitive score on the Alzheimer’s Disease Assessment Scale changed by -0.17 points in the nicergoline group and worsened by 1.38 points in the placebo group. The difference was statistically significant.

Total Alzheimer’s Disease Assessment Scale scores also favoured nicergoline. Non-cognitive symptoms showed a numerical advantage, although the difference did not reach statistical significance. Measures of daily functioning deteriorated slightly in both groups without a clear treatment difference.

A US trial reported gradual improvement in cognitive scores during the first months of nicergoline treatment while scores in the placebo group initially worsened. A late improvement in the placebo group reduced the final difference, leaving the six-month cognitive result non-significant. Global ratings still showed some advantage for nicergoline.

The Alzheimer’s-specific trials therefore suggest a small cognitive advantage, while effects on daily functioning were less convincing.

Nicergoline in Vascular and Mixed Dementia

Nicergoline has also been studied in vascular dementia, multi-infarct dementia and mixed forms of cognitive decline. Its vascular, metabolic and neurotransmitter effects made these conditions a major focus of early research.

In an Italian study involving 315 patients with mixed forms of dementia, nicergoline produced greater improvements than placebo across cognitive dysfunction, apathy, interpersonal relationships and somatic functioning.

A 12-month study involving 108 patients with Alzheimer’s disease, multi-infarct dementia or mixed dementia found that mean geriatric assessment scores improved with nicergoline and worsened with placebo. Mini-Mental State Examination scores remained broadly stable in the nicergoline group while declining in the placebo group.

Several other trials reported improvements in memory, attention, behaviour and global clinical ratings. Because many studies combined different causes of dementia, they offer limited guidance about which diagnostic group was most likely to respond.

Does Nicergoline Slow Cognitive Decline?

Some longer studies found that patients receiving nicergoline were more likely to remain stable or improve.

In the 12-month mixed-dementia study, investigators rated 53% of patients taking nicergoline as improved and 12% as worsened. In the placebo group, 10% improved and 32% worsened. Approximately 90% of nicergoline-treated patients improved or remained stable, compared with about 68% of placebo-treated patients.

A follow-up of the European Alzheimer’s trial also found that cognitive scores deteriorated less over twelve months in the nicergoline group. The mean Alzheimer’s Disease Assessment Scale cognitive score worsened by about two points with nicergoline and four points with placebo.

These findings could reflect sustained symptom control, slower measured decline or a combination of both. The studies assessed performance on cognitive and global rating scales rather than changes in amyloid, tau or neuronal loss.

Very few trials continued beyond one year, and none used the biomarkers or imaging methods now expected in disease-modification research. The longer-term findings remain clinically interesting, but they cannot determine whether nicergoline altered the underlying neurodegenerative process.

How Meaningful Were the Improvements?

The 2008 review reports that up to 89% of patients improved in some studies. That figure came from responder analyses based largely on clinician-rated global scales.

Responder classifications can show whether a patient was judged better overall, but they do not always reveal the size of the change or whether it improved independence in daily life. The review itself notes that global assessments may be partly subjective.

The Alzheimer’s-specific cognitive results were more modest. In the large European trial, the difference between nicergoline and placebo on the Alzheimer’s Disease Assessment Scale cognitive score was statistically significant but small. Functional measures did not show a clear benefit.

The responder analyses are therefore best read as evidence that some patients were judged better overall. The smaller changes on Alzheimer’s-specific scales give a more realistic sense of the likely effect size.

Why the Human Evidence Is Hard to Interpret

Most nicergoline dementia trials were conducted between the 1970s and 1990s. Dementia diagnosis and clinical trial methodology have changed substantially since then.

Several studies used the Sandoz Clinical Assessment-Geriatric scale, which combines cognitive symptoms with affective problems, apathy, interpersonal relationships and physical complaints. Improvements in non-cognitive areas could influence the total score, making it difficult to isolate changes in memory.

The studies also used broad categories such as senile dementia, multi-infarct dementia and chronic cerebrovascular disorders. These populations may have included people with Alzheimer’s disease, vascular impairment, depression, mixed pathology or other causes of cognitive decline.

Additional limitations include small samples, relatively short treatment periods, inconsistent outcome measures and limited comparisons with other dementia drugs. Few studies examined institutionalisation, caregiver burden, loss of independence or progression to severe dementia.

The 2008 review states that its writing assistance was funded by Pfizer Central and Eastern Europe. This does not invalidate the studies it summarised, but it is a relevant potential source of bias.

What Did the Mouse Study Find?

A 2018 study examined nicergoline in 3xTg-AD mice, an experimental model designed to reproduce several Alzheimer’s-related features.

Twenty mice were divided into two groups. One group received intravenous nicergoline at 10 mg/kg once daily for 60 days, while the control group received phosphate-buffered saline. The researchers assessed learning, behaviour, hippocampal cell survival, inflammation, oxidative stress and amyloid-related markers.

Nicergoline-treated mice performed better in behavioural and learning tests. Their hippocampi showed fewer apoptotic cells and lower expression of several pro-apoptotic proteins, including caspase-3, Bax, Bid and caspase-9. The study also reported lower levels of inflammatory markers such as interleukin-1, interleukin-6 and tumour necrosis factor-alpha.

Staining for amyloid-beta 40, amyloid-beta 42 and amyloid precursor protein was reduced in the hippocampus. The researchers also identified changes in proteins associated with oxidative stress, neuroprotection and neuronal growth.

The Role of PI3K/AKT Signalling

The mouse study proposed that nicergoline’s effects involved the PI3K/AKT pathway, which contributes to cell survival, growth and inflammatory regulation.

Nicergoline increased PI3K and AKT expression and promoted AKT phosphorylation in hippocampal cells. When researchers added the PI3K inhibitor LY294002, several of nicergoline’s cellular effects were weakened. Inflammation, oxidative stress and apoptosis increased again after PI3K inhibition.

The experimental findings therefore support activation of PI3K/AKT signalling as part of the observed neuroprotective response.

The paper uses inconsistent wording in several places. Its abstract and conclusion sometimes refer to inhibition of PI3K/AKT, while the results and figures describe increased PI3K expression, AKT expression and AKT phosphorylation. The reported experimental data align more clearly with pathway activation.

What the Animal Study Cannot Show

The mouse study included only 20 animals and used daily intravenous nicergoline at 10 mg/kg. Human dementia trials generally used oral doses of about 60 mg per day, so the treatment methods are not directly comparable.

Mouse water-maze performance is also different from human memory, language, judgement and daily independence. Changes in amyloid staining and cell signalling over 60 days mainly help identify possible mechanisms.

The study is most useful for explaining how nicergoline might affect neuronal survival, inflammation and PI3K/AKT signalling. It does not resolve the uncertainties in the older clinical literature.

Is Nicergoline Safe?

Most adverse effects reported in clinical trials were described as mild and temporary.

Reported problems included dizziness, fatigue, drowsiness, sleep disturbance, flushing, headache, nausea, diarrhoea and abdominal discomfort. Some studies also reported hallucinations, agitation, delusions or changes in taste, although these events were uncommon.

Across randomised trials, adverse-event rates were often similar between nicergoline and placebo, although some pooled analyses found a slightly higher overall rate with nicergoline. Treatment withdrawal due to adverse effects was generally uncommon.

Long-term safety is less certain because many studies were old, relatively short or not designed to detect rare complications.

Blood Pressure and Cardiovascular Effects

Nicergoline can affect vascular tone through alpha-1 adrenergic receptor blockade.

Reported cardiovascular effects include hypotension, temporary increases in blood pressure, bradycardia, syncope and dizziness. Most were minor and did not require treatment withdrawal. One case report described Prinzmetal angina in a 56-year-old woman, with symptoms resolving after nicergoline was stopped.

The 2008 review lists recent myocardial infarction, acute bleeding, severe bradycardia and orthostatic hypotension among the contraindications reported in product information.

These risks are particularly important in older adults who already take blood-pressure medication or have cardiovascular disease.

Uric Acid and Gout

Nicergoline can increase serum uric acid.

Most reported increases did not cause symptoms or require treatment. The Nicergoline Cooperative Study Group reported hyperuricaemia in several patients and one case of gout in a person who already had elevated uric acid.

A history of gout, hyperuricaemia or treatment with medicines that affect uric acid metabolism may therefore require additional caution.

Fibrosis, Ergotism and Other Rare Reactions

Nicergoline is an ergot derivative, which has raised concerns about fibrosis and ergotism.

A 1996 report described four patients who developed chronic pleural thickening or pleural effusion while taking nicergoline. Their conditions slowly improved after treatment was withdrawn. The 2014 review also notes that a systematic review found no published cases of ergotism clearly attributed to nicergoline.

Rare complications are difficult to quantify when long-term surveillance is limited. Other isolated reports include interstitial nephritis, Prinzmetal angina and inhibition of ejaculation.

Nicergoline Drug Interactions

Nicergoline may interact with several medication classes commonly used by older adults.

Its vasodilating effects may be enhanced by antihypertensive drugs, other vasodilators and beta blockers. One study reported that nicergoline potentiated the cardiac effects of propranolol.

Nicergoline also inhibits platelet aggregation and may reduce blood viscosity. People taking anticoagulants or antiplatelet drugs may require closer monitoring because of the potential for increased bleeding risk.

CYP2D6 contributes to nicergoline metabolism. The safety review raises the possibility of interactions with CYP2D6 substrates, inhibitors and inducers, including some antidepressants, antipsychotics, beta blockers and other medicines. The clinical importance of many of these potential interactions has not been adequately tested.

Polypharmacy makes these concerns particularly relevant in people being treated for dementia or vascular disease.

Bottom Line

Nicergoline produced modest improvements in cognition, behaviour or overall clinical ratings in several older placebo-controlled dementia trials. Some longer studies also found that patients taking nicergoline were more likely to remain stable or deteriorate less than those receiving placebo.

The size of the benefit was usually limited. Alzheimer’s-specific cognitive scales showed smaller effects than the most favourable responder figures, and measures of daily functioning were inconsistent. The trials also predated current diagnostic criteria, biomarker-based research and modern standards for demonstrating disease modification.

The 2018 mouse study adds a plausible neuroprotective mechanism involving hippocampal cell survival, inflammation and PI3K/AKT signalling. It strengthens the biological rationale for nicergoline without updating the human clinical evidence.

Nicergoline remains an older drug with a credible clinical signal and an incomplete modern evidence base. Its cardiovascular effects, uric acid changes and interactions with antiplatelet, anticoagulant and CYP2D6-related medicines also make clinician oversight essential, particularly in older adults taking multiple medications.

References

Saletu, B., Garg, A., & Shoeb, A. (2014). Safety of nicergoline as an agent for management of cognitive function disorders. BioMed Research International, 2014, Article 610103. https://doi.org/10.1155/2014/610103

Winblad, B., Fioravanti, M., Dolezal, T., Logina, I., Milanov, I. G., Popescu, D. C., & Solomon, A. (2008). Therapeutic use of nicergoline. Clinical Drug Investigation, 28(9), 533–552. https://doi.org/10.2165/00044011-200828090-00001

Zang, G., Fang, L., Chen, L., & Wang, C. (2018). Ameliorative effect of nicergoline on cognitive function through the PI3K/AKT signaling pathway in mouse models of Alzheimer’s disease. Molecular Medicine Reports, 17(5), 7293–7300. https://doi.org/10.3892/mmr.2018.8786